Showing results (1-10 of 827) with videos related to
Sort By:
Pageof 83
Current Opinion in Rheumatology|April 4, 2009
Costimulation blockade in rheumatic diseases: where we are?Vincent Goëb, Maya H Buch, Edward M Vital, et al.Arthritis Research & Therapy|November 26, 2008
Abatacept in the treatment of rheumatoid arthritisMaya H Buch, Edward M Vital, Paul EmeryAnnals of the Rheumatic Diseases|January 21, 2014
An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trialEdward M Vital, Shouvik Dass, Maya H Buch, et al.Current Opinion in Rheumatology|March 24, 2011
New therapies in the management of rheumatoid arthritisMaya H Buch, Paul EmeryTherapeutics and Clinical Risk Management|March 25, 2008
Abatacept in the treatment of rheumatoid arthritisEdward M Vital, Paul EmeryJournal of Autoimmunity|May 27, 2008
The development of targeted therapies in rheumatoid arthritisEdward M Vital, Paul EmeryCurrent Rheumatology Reports|August 21, 2015
B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During UseMd Yuzaiful Md Yusof, Edward M Vital, Maya H BuchDrug, Healthcare and Patient Safety|June 25, 2011
Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerationsSarah Horton, Maya H Buch, Paul EmeryAnnals of the Rheumatic Diseases|January 4, 2014
Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapySudipto Das, Edward M Vital, Sarah Horton, et al.Pageof 83